42802-94-8Relevant articles and documents
COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER
-
Page/Page column 13, (2018/09/25)
The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin- 4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).
ERK INHIBITORS
-
Paragraph 0080, (2016/07/27)
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
Self-assembly of pseudo-rotaxane and rotaxane complexes using an electrostatic slippage approach
Catalán, Aldo C.,Tiburcio, Jorge
supporting information, p. 9526 - 9529 (2016/08/01)
The protonation of a cyclic tertiary amine, integrated into the structure of a dumbbell-shaped guest molecule, accelerates the sliding of the guest through the cavity of a crown ether macrocycle to yield a stable pseudo-rotaxane complex. The use of an amine with the appropriate ring size followed by a proton transfer reaction leads to the formation of an interlocked rotaxane species.
Pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors
-
Paragraph 0149; 0154; 0155; 0156, (2016/10/08)
The present invention discloses a class of pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors, and particularly relates to a compound represented by a formula (I) or a pharmaceutically acceptable salt thereof. The formula (I) is defined in the specification.
